Therapeutic advances in multiple sclerosis

JH Yang, T Rempe, N Whitmire, A Dunn-Pirio… - Frontiers in …, 2022‏ - frontiersin.org
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

Progressive multiple sclerosis: from pathophysiology to therapeutic strategies

S Faissner, JR Plemel, R Gold, VW Yong - Nature reviews drug …, 2019‏ - nature.com
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that
involves demyelination and axonal degeneration. Although substantial progress has been …

Applications of deep learning techniques for automated multiple sclerosis detection using magnetic resonance imaging: A review

A Shoeibi, M Khodatars, M Jafari, P Moridian… - Computers in Biology …, 2021‏ - Elsevier
Multiple Sclerosis (MS) is a type of brain disease which causes visual, sensory, and motor
problems for people with a detrimental effect on the functioning of the nervous system. In …

Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

E Kamma, W Lasisi, C Libner, HS Ng… - Journal of …, 2022‏ - Springer
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …

Treatment of multiple sclerosis—success from bench to bedside

M Tintore, A Vidal-Jordana… - Nature Reviews …, 2019‏ - nature.com
The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

J Sastre-Garriga, D Pareto, M Battaglini… - Nature Reviews …, 2020‏ - nature.com
Early evaluation of treatment response and prediction of disease evolution are key issues in
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …

Epidemiology and treatment of multiple sclerosis in elderly populations

CB Vaughn, D Jakimovski, KS Kavak… - Nature Reviews …, 2019‏ - nature.com
The prevalence of multiple sclerosis (MS) and the age of affected patients are increasing
owing to increased longevity of the general population and the availability of effective …

[HTML][HTML] Reviewing the significance of blood–brain barrier disruption in multiple sclerosis pathology and treatment

R Balasa, L Barcutean, O Mosora, D Manu - International journal of …, 2021‏ - mdpi.com
The disruption of blood–brain barrier (BBB) for multiple sclerosis (MS) pathogenesis has a
double effect: early on during the onset of the immune attack and later for the CNS self …

Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data

A Eshaghi, AL Young, PA Wijeratne, F Prados… - Nature …, 2021‏ - nature.com
Multiple sclerosis (MS) can be divided into four phenotypes based on clinical evolution. The
pathophysiological boundaries of these phenotypes are unclear, limiting treatment …

The COVID-19 pandemic and the use of MS disease-modifying therapies

G Giovannoni, C Hawkes… - Multiple sclerosis …, 2020‏ - pmc.ncbi.nlm.nih.gov
Maria was distraught after reading about the 'potential'epidemic, yet to happen, and the
horror stories on Facebook needing reassurance and certainty about what she should do …